TY - JOUR
AU - Garcia-Aguilar, Julio
AB - Ann Surg Oncol (2016) 23:2548–2555 DOI 10.1245/s10434-016-5205-4 OR IGINAL ARTIC L E – COLORECTAL CANCER KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy 1 2 2 2 Oliver S. Chow, MD , Deborah Kuk, ScM , Metin Keskin, MD , J. Joshua Smith, MD, PhD , Niedzica Camacho, 2 2 2 3 2 PhD , Raphael Pelossof, PhD , Chin-Tung Chen, MS , Zhenbin Chen, PhD , Karin Avila, MS , Martin R. Weiser, 2 2 2 4 2 MD , Michael F. Berger, PhD , Sujata Patil, PhD , Emily Bergsland, MD , and Julio Garcia-Aguilar, MD, PhD 1 2 Beth Israel Deaconess Medical Center, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; 3 4 University of Alabama at Birmingham, Birmingham, AL; University of California, San Francisco, CA ABSTRACT only 2 (7 %) achieved pCR. Tumors with both KRAS and Background. The response of rectal cancers to neoadju- TP53 mutation were associated with lymph node metasta- vant chemoradiation (CRT) is variable, but tools to predict sis. The concordance between platforms was high for response remain lacking. We evaluated whether KRAS and KRAS (40 of 43, 
TI - KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy
JF - Annals of Surgical Oncology
DO - 10.1245/s10434-016-5205-4
DA - 2016-03-28
UR - https://www.deepdyve.com/lp/springer-journals/kras-and-combined-kras-tp53-mutations-in-locally-advanced-rectal-0AfXXYL5j1
SP - 2548
EP - 2555
VL - 23
IS - 8
DP - DeepDyve
ER -